<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99041">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01776658</url>
  </required_header>
  <id_info>
    <org_study_id>SYL1001_II</org_study_id>
    <nct_id>NCT01776658</nct_id>
  </id_info>
  <brief_title>Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sylentis, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sylentis, S.A.</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot study is to compare the analgesic effect of SYL1001 versus placebo in
      patients with ocular pain associated with Dry Eye Syndrome. General and local tolerability
      are also evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes from Baseline in the Ocular Pain Scores on the Visual Analog Scale (VAS) and in the Ocular Discomfort Scores on the Ocular Surface Disease Index (OSDI) as a Measure of SYL1001 Analgesic Effect versus Placebo.</measure>
    <time_frame>10 days + (4-10 days)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Simple Corneal and Conjunctival Evaluation as a Measure of Safety and Tolerability using Ophthalmic Dyes and a Slit Lamp</measure>
    <time_frame>10 days + (4-10 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Adverse Events Appearance as a measure of SYL1001 tolerability</measure>
    <time_frame>10 days + (96-240 hours)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Vital Signs, Blood, Urine and Ocular Parameters Alterations (IOP, Visual Acuity, Anterior Segment Exploration) Possibly Related to the Investigational Product</measure>
    <time_frame>10 days + (96-240 hours)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ocular Pain</condition>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>SYL1001 eye drops dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocular topical administration of SYL1001 eye drops dose A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ocular topical administration of placebo eye drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYL1001</intervention_name>
    <description>Ocular topical administration of SYL1001 for 10 consecutive days</description>
    <arm_group_label>SYL1001 eye drops dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ocular topical administration of placebo for 10 consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both genders

          -  Age ≥ 18 years old

          -  Give written informed consent to participate in the study after having been informed
             of the study design, objectives and possible derived risks

          -  Common mild to moderate dry eye symptoms. Persistent daily symptoms for more than
             three months:

          -  OSDI scale: 13-30

          -  VAS scale: 2-7

          -  Ocular tests in both eyes:

          -  Corneal staining with fluorescein. Oxford scale &gt; 0

          -  Tear Breakup Time Test: (BUT) &lt; 10 seconds

          -  Schirmer test with anaesthesia &lt; 10 mm/5min

        Exclusion Criteria:

          -  Pregnant or breastfeeding females or those with a positive pregnancy test.

          -  Females of childbearing potential who will not use a medically acceptable
             contraceptive method from selection and during the whole study.

          -  Current relevant disease, including respiratory disease, cardiovascular, endocrine,
             neurological, haematological, renal, neoplasic, hepatopathy, gastrointestinal
             distress, hypertension, or infectious acute processes.

          -  Past history of a chronic o recurring condition that could interfere with study
             according to the investigator's judgement.

          -  Concomitant use of other drugs with analgesic activity by any route of administration
             at the enrolment period.

          -  Changes in any ocular and/or systemic concomitant medication one month prior to the
             study commencement and during the study development.

          -  Changes on the preestablished artificial tears dosage 15 days prior to the study
             commencement and during the study development.

          -  Cyclosporine treatment initiation or changes in cyclosporine dosage or dosing regimen
             during the 6 months prior to enrolment.

          -  Previous history of drug hypersensitivity.

          -  Use of contact lenses

          -  Case history of drug or alcohol abuse or dependence.

          -  Relevant abnormal laboratory results as judged by the investigator

          -  Previous refractive surgery

          -  Participation in a clinical trial within 2 months before the enrolment visit

          -  Relevant ocular pathology judged by the investigator.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Verónica Ruz, PhD</last_name>
    <email>vruz@sylentis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Oftalmológico Fernández-Vega</name>
      <address>
        <city>Oviedo</city>
        <zip>33012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 23, 2013</lastchanged_date>
  <firstreceived_date>November 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ocular pain</keyword>
  <keyword>Dry Eye Syndrome</keyword>
  <keyword>siRNA</keyword>
  <keyword>RNAi</keyword>
  <keyword>TRPV1</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
